An animal vaccine research and development company said Wednesday that it will move its global commercial operations to Overland Park.
Prommune Inc., now at the University of Nebraska Medical Center in Omaha, specializes in the production of swine flu and avian flu vaccines.
The company will operate temporarily from an administrative office at 9393 W. 110th St. It expects to hire up to six employees in the first three years, with additional marketing and sales personnel added later.
Sam Al-Murrani of Babylon BioConsulting is the interim chief executive officer for Prommune. He said the KC Animal Health Corridor “provides unsurpassed logistics, manufacturing and a pool of potential qualified employee mix that a company focused on animal health can ill afford to ignore.”
Al-Murrani said Prommune eventually plans to consolidate laboratory operations in the Kansas City area. Lab work will continue for several more months at the University of Nebraska, where clinical trials make it inconvenient to move equipment now, he said.
The company will look for about 1,000 square feet of space in the Kansas City market, with expectations to expand to 3,000 square feet, he said.
“We’ll be looking to hire mostly scientific positions in Overland Park initially and then will hire high-end technical salespeople who’ve had experience in pharmaceutical sales,” Al-Murrani said.
The Kansas City Area Development Council said it led a recruiting team to attract Prommune to locate in the KC Animal Health Corridor.